机器人对比腹腔镜右半结肠癌根治术的随机II期试验
RoLaCaRT-1为国际多中心前瞻性随机II期预试验,右半结肠腺癌患者按2:1随机分配至机器人(RRHC,19例)或腹腔镜(LRHC,10例)右半结肠切除术。主要终点90天手术并发症指数(CCI)在RRHC组显著更低(30天中位数0 vs 21,差值21,95%CI 9-26,p=0.005;90天p=0.008),病理质量与生活质量无显著差异,支持开展更大规模随机试验。
要点
- 机器人右半结肠切除术30天和90天CCI显著低于腹腔镜组。
- 两组均无手术死亡、均获R0切除,CME率与完整系膜率相近。
- 病理质量与生活质量无显著差异,术者任务负荷倾向机器人组。
核心结论
- 机器人右半结肠切除术较腹腔镜改善了短期手术并发症和术者体力需求与操作表现。
- 两组生活质量与病理标本质量相似,支持开展更大规模随机试验。
研究设计与样本
- 国际多中心前瞻性随机II期预试验,右半结肠腺癌患者按2:1随机分配至机器人或腹腔镜手术。
- 由认证术者实施手术,机器人组19例、腹腔镜组10例。
- 主要终点为采用综合并发症指数(CCI)测量的90天手术并发症。
主要发现
- 平均手术时间机器人组3.8小时、腹腔镜组3.1小时,两组均无手术死亡。
- 两组均获R0切除,CME率53% vs 50%,完整系膜率94% vs 100%。
- CCI在机器人组30天和90天均显著更低(30天中位数0(0,9)vs 21(21,26),中位差值21,95%CI 9-26,p=0.005;90天p=0.008)。
- 病理数据与生活质量数据无显著差异,术者任务负荷数据倾向机器人手术。
- 中位随访6个月,因资金有限研究提前终止。
关键数值与推荐
- 主要终点CCI在机器人组30天中位数0(Q1,Q3:0,9),腹腔镜组21(21,26)。
- 中位差值21,95%CI 9-26,30天p=0.005,90天p=0.008。
临床怎么用
- 对右半结肠癌,机器人右半结肠切除术可能降低短期手术并发症并减轻术者体力负荷。
- 在病理标本质量和生活质量方面,机器人手术与腹腔镜手术结果相似。
局限性
- 样本量小(机器人组19例、腹腔镜组10例),为预试验。
- 因资金有限提前终止研究。
- 中位随访仅6个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous stage I-III colon cancer trials demonstrated improved peri-operative and similar long-term oncological outcomes with minimally invasive approaches compared with open surgery. Subsequent technical developments, including intracorporeal anastomosis, complete mesocolic excision (CME), refined pathologic grading systems and robotic approaches are increasingly used despite minimal supporting evidence. This international phase II trial aims to assess patient, surgical and pathological outcomes following robotic (RRHC) with laparoscopic right hemicolectomy (LRHC) for right sided colon cancer. METHODS: Prospective, international multicentre pilot randomised phase II trial for patients with right colon adenocarcinoma, randomised 2:1 to robotic (RRHC) or laparoscopic (LRHC) surgery performed by accredited surgeons. Primary outcome was 90-day surgical morbidity measured using the Comprehensive Complication Index (CCI). Standardised pathology reviews, patient reported quality of life and surgeon task load index data was captured. RESULTS: RRHC vs. LRHC surgery allocation was 19 vs. 10, mean operative time 3.8 vs. 3.1 h with no operative mortality, all had R0 resection, CME rate 53 vs. 50% and intact mesocolon 94 v 100%. CCI was significantly lower at 30 and 90 days after RRHC (median (Q1, Q3): 0 (0, 9) vs. 21 (21, 26); median difference: 21; 95% CI 9-26; p = 0.005 at 30 days; p = 0.008 at 90 days). No significant differences in pathological nor quality of life data was observed. Surgeons task load data tended to favour robotic procedures. Median follow-up was 6 months. Limited funding led to early study closure. CONCLUSIONS: RRHC improved short-term surgical morbidity and surgeon physical demand and performance whilst obtaining similar quality of life and pathological specimen quality compared to LRHC for right sided colon cancer, supporting the case for larger randomised trials. TRIAL REGISTRATION: ACTRN12620001378910.
引用
- Stevenson ARL, Khan JS, Wilson K, et al. RoLaCaRT-1: pilot randomised phase II study of robotic vs laparoscopic hemicolectomy for right colon cancer. Surg Endosc. 2025. PMID: 41372621. doi:10.1007/s00464-025-12400-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。